fenofibrate has been researched along with mbx-8025 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Bates, J; Breckenridge, DG; Hollenback, D; Kusam, S; Mahadevan, S; Marchand, B; Okesli-Armlovich, A; Olson, I; Seung, M; Toteva, M; Trevaskis, JL; Vijayakumar, A; Wang, T | 1 |
1 review(s) available for fenofibrate and mbx-8025
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
1 other study(ies) available for fenofibrate and mbx-8025
| Article | Year |
|---|---|
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Topics: Acetates; Acetyl-CoA Carboxylase; Animals; Fenofibrate; Humans; Hypertriglyceridemia; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Triglycerides | 2022 |